Nevro today announced that it received two patents for its Senza High-Frequency Spinal Cord Stimulation System, a device aimed at patients with chronic pain.
The first patent concerns the device's methods for delivering pulsed electrical signals to the epidural space of the spinal cord to relieve a patient's chronic leg or back pain without creating paresthesia. An additional patent includes claims that correspond to many of the method claims of the first patent.
The patents represent an "important milestone" in the development of spinal cord stimulation technology, said Michael DeMane, Nevro president and CEO.
Greenwich Hospital Physicians Honored for Pain Management
Low-Dose Diclofenac Reduces Post-Op Pain in Phase 3 Trial
The first patent concerns the device's methods for delivering pulsed electrical signals to the epidural space of the spinal cord to relieve a patient's chronic leg or back pain without creating paresthesia. An additional patent includes claims that correspond to many of the method claims of the first patent.
The patents represent an "important milestone" in the development of spinal cord stimulation technology, said Michael DeMane, Nevro president and CEO.
Related Articles on Pain Management:
Growing a Comprehensive Pain Management Practice: Q&A With Pain Specialists of CharlestonGreenwich Hospital Physicians Honored for Pain Management
Low-Dose Diclofenac Reduces Post-Op Pain in Phase 3 Trial